fda glp-1 warning 2025 november September 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines Covering GLP-1 Drugs: Employers' Top

Understanding of gustatory coding helps to predict, and perhaps even modulate the ingestive decision circuitry, especially when eating behaviour becomes dysfunctional

Discover how it compares to injectable weight-loss medications and if it's right for you.

Millions of people starting semaglutide wonder if their morning coffee habit needs to change

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common disease that happens when fat builds up in your liver

While the world has focused on the battle between injectables and oral tablets, the "Mucosal Frontier" addresses the three biggest hurdles in peptide therapy: 1 Bioavailability: By utilizing a mucosal delivery platform, the drug avoids first-pass metabolism in the liver, potentially offering a more efficient way for the body to utilize the peptide compared to traditional oral versions